WHOCC
Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
Postboks 222 Sk°yen
0213 Oslo
Norway

Visiting/delivery address:
Sandakerveien 24C
Bygg C
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

List of DDDs for 3 years revision

The DDDs, which will be reviewed at the March 2022 meeting (3 year revision) are listed below.  See also Guidelines: Part III; D Principles for reviewing and changing DDD and Part V; D Requests for changes to DDDs. The deadline for applications for alterations and comments is 1 February 2022.  

 

ATC codeATC level name (INN/generic name)DDDUnitAdm.route
A04AD11nabilone3mgO
A10BJ06semaglutide0.11mgP
A16AB17cerliponase alfa21mgP
A16AX09glycerol phenylbutyrate15gO
G03XX01prasterone6.5mgV
G04BX15pentosan polysulfate sodium0.3gO
J01AA14sarecycline0.1 gO
J01AA15omadacycline0.3gO
J01AA15omadacycline0.1 gP
J01DD64cefpodoxime and beta-lactamase inhibitor0.4 1)gO
J01MA12levofloxacin0.24gInhal.solution
J04AA03calcium aminosalicylate15gO
J04AB06enviomycin1gP
J05AB03vidarabine0.7gP
J05AG06doravirine0.1gO
J05AH03peramivir0.6gP
J05AH04laninamivir40mgInhal.powder
J05AP06asunaprevir0.2gO
J05AP10elbasvir50mgO
J05AP11grazoprevir0.1gO
J05AX25baloxavir marboxil40mgO
J05AX26amenamevir0.4gO
J05AX27favipiravir1.6gO
L02BB05apalutamide0.24gO
L04AB07opinercept7mgP
L04AC12brodalumab15mgP
M03BX03pridinol6mgO
M04AB05lesinurad0.2gO
N02CD01erenumab2.5mgP
N02CD02galcanezumab4mgP
N02CD03fremanezumab7.5mgP
P01CA03fexinidazole1.44gO
V03AE10sodium zirconium cyclosilicate7.5mgO
1) Refers to cefpodoxime

Last updated: 2021-12-08